Pembrolizumab, olaparib, and temozolomide for recurrent glioma
Treatments studied
Part of Cancer clinical trials.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent before any study testing.
- Your glioma is confirmed by biopsy as grade 2 or 3, with specific IDH findings (either IDH-mutated without a certain CDKN2A/B loss, or IDH-wildtype with certain repair gene changes).
- Your tumor must have measurable disease on MRI (doctors use the RANO way to judge this) and must show clear progression compared with a prior scan.
- You must be on a stable (unchanging) steroid dose for at least 4 weeks before the baseline MRI, and the dose must be low (no more than 2 mg/day dexamethasone or equivalent).
- You must be able to take and keep down oral medicines and have brain MRI scans with contrast (dye).
- You need enough blood, kidney, liver, and clotting function based on lab tests, and you must have recovered from prior treatment effects (not worse than mild, except for hair loss or mild nerve symptoms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.